Progress in neoadjuvant therapy for hepatocellular carcinoma based on immune checkpoint inhibitors
10.3969/j.issn.1005-6483.20241484
- VernacularTitle:以免疫检查点抑制剂为基础的肝细胞癌新辅助治疗进展
- Author:
Hao WANG
1
;
Binyong LIANG
1
;
Bin MEI
1
Author Information
1. 430030 武汉,华中科技大学同济医学院附属同济医院肝脏外科
- Publication Type:Journal Article
- Keywords:
hepatocellular carcinoma;
neoadjuvant therapy;
immune checkpoint inhibitors
- From:
Journal of Clinical Surgery
2025;33(3):332-335
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC)primarily relies on surgical resection for curative treatment,but the high recurrence rate after surgery is a pressing issue that needs to be addressed.Neoadjuvant immunotherapy,represented by immune checkpoint inhibitors(ICIs),has the potential to reduce postoperative recurrence,increase the rate of radical resection,and prolong survival time.The combination of ICIs with other treatments is gradually becoming a hot area in clinical research for liver cancer.
